title: Current issues in the economics of vaccination against dengue.
abstract: Dengue is a major public health concern in tropical and subtropical areas of the world. The prospects for dengue prevention have recently improved with the results of efficacy trials of a tetravalent dengue vaccine. Although partially effective, once licensed, its introduction can be a public health priority in heavily affected countries because of the perceived public health importance of dengue. This review explores the most immediate economic considerations of introducing a new dengue vaccine and evaluates the published economic analyses of dengue vaccination. Findings indicate that the current economic evidence base is of limited utility to support country-level decisions on dengue vaccine introduction. There are a handful of published cost-effectiveness studies and no country-specific costing studies to project the full resource requirements of dengue vaccine introduction. Country-level analytical expertise in economic analyses, another gap identified, needs to be strengthened to facilitate evidence-based decision-making on dengue vaccine introduction in endemic countries.
authors.affiliation: a College of Global Public Health , New York University , New York , NY , USA.
authors.forename: Yesim
authors.initials: Y
authors.lastname: Tozan
mesh_terms: D003362:Cost-Benefit Analysis; D003715:Dengue / Q000453:epidemiology / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology* / Q000302:isolation & purification; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D019353:Endemic Diseases; D006801:Humans; D014611:Vaccination / Q000191:economics*
chemical_list: D053059:Dengue Vaccines
keywords: Dengue vaccination; affordability; cost-effectiveness; dengue; dengue vaccines; developing countries; economic evaluation; low- and middle-income countries; national immunization programs; sustainability